Navidea Biopharmaceuticals Inc. appears to have avoided a proxy fight, but a departing executive – once part of its biggest investor – fired a blistering salvo at top management.
The Dublin developer of radioactive diagnostic and therapeutic drugs late Monday said it would be late filing its annual report with the Securities and Exchange Commission while resolving the books of its Macrophage Therapeutics Inc. subsidiary, and that the division’s CEO and COO would resign.
Navidea (NYSEMKT:NAVB) also said it would seat two directors that shareholders intended to nominate, while another director stepped down, as part of an agreement to reaffirm its loan from New York City-based Platinum Management LLC.
